Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy

Walter Fiedler

doi:10.1111/bjh.19311

Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy

Standard

Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy. / Fiedler, Walter.

in: BRIT J HAEMATOL, Jahrgang 204, Nr. 4, 04.2024, S. 1135-1136.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Kommentar › Forschung

Harvard

Fiedler, W 2024, 'Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy', BRIT J HAEMATOL, Jg. 204, Nr. 4, S. 1135-1136. https://doi.org/10.1111/bjh.19311

APA

Fiedler, W. (2024). Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy. BRIT J HAEMATOL, 204(4), 1135-1136. https://doi.org/10.1111/bjh.19311

Vancouver

Fiedler W. Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy. BRIT J HAEMATOL. 2024 Apr;204(4):1135-1136. https://doi.org/10.1111/bjh.19311

Bibtex

@article{65842cdbbf884314b278b5c725cacaed,

title = "Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy",

abstract = "Patients with newly diagnosed acute myeloid leukaemia and severe acute complications, such as respiratory failure or sepsis, suffer from a high mortality rate when induction chemotherapy is delivered in an ICU setting. The report by Liang et al. implies that less intensive therapy with hypomethylating agents/venetoclax results in a lower mortality and morbidity rate whereby preserving efficacy in this patient group. Commentary on: Liang et al. Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukemia. Br J Haematol 2024;204:1219-1226.",

author = "Walter Fiedler",

note = "{\textcopyright} 2024 British Society for Haematology and John Wiley & Sons Ltd.",

year = "2024",

month = apr,

doi = "10.1111/bjh.19311",

language = "English",

volume = "204",

pages = "1135--1136",

journal = "BRIT J HAEMATOL",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

RIS

TY - JOUR

T1 - Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy

AU - Fiedler, Walter

PY - 2024/4

Y1 - 2024/4

N2 - Patients with newly diagnosed acute myeloid leukaemia and severe acute complications, such as respiratory failure or sepsis, suffer from a high mortality rate when induction chemotherapy is delivered in an ICU setting. The report by Liang et al. implies that less intensive therapy with hypomethylating agents/venetoclax results in a lower mortality and morbidity rate whereby preserving efficacy in this patient group. Commentary on: Liang et al. Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukemia. Br J Haematol 2024;204:1219-1226.

AB - Patients with newly diagnosed acute myeloid leukaemia and severe acute complications, such as respiratory failure or sepsis, suffer from a high mortality rate when induction chemotherapy is delivered in an ICU setting. The report by Liang et al. implies that less intensive therapy with hypomethylating agents/venetoclax results in a lower mortality and morbidity rate whereby preserving efficacy in this patient group. Commentary on: Liang et al. Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukemia. Br J Haematol 2024;204:1219-1226.

U2 - 10.1111/bjh.19311

DO - 10.1111/bjh.19311

M3 - Comment/debate

C2 - 38228122

VL - 204

SP - 1135

EP - 1136

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 4

ER -